Drug Database · Clinicians

Amino acids

Brands (21) Aminoleban, Aminovit, Nutrimax…Show all

Part of: Parenteral nutrition products (Drug Index, by product type)

Parenteral nutrition (amino acids); Nutritional supplement PH FDA category

Rx · Prescription drug24 PH productsPNF-listed PN kidney notes reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Parenteral nutrition: kidney notes

Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.

Brands: Aminoleban · Aminosteril Infant · Aminosteril N-Hepa 8% · Aminoven · Evamin · Nephrosteril

Kidney notes: Aminoleban

Aminoleban 8% (Otsuka) is an amino acid infusion rich in branched-chain amino acids, indicated for improvement of encephalopathy in chronic liver disease. Philippine registrations: 500 ml LDPE bottle, and 200 ml and 500 ml polypropylene soft bags, made by Otsuka Pharmaceutical Vietnam. It is a hepatic formula, not a kidney formula.

Composition

Per presentation200 ml500 ml
Total free amino acids (g)15.9839.93
Nitrogen (g)2.446.11
Sodium, approx. (mEq)37
Chloride, approx. (mEq)1947
  • Branched-chain amino acids 35.5% (w/w); Fischer ratio 37.05; osmotic pressure ratio about 3 relative to physiological saline; pH 5.5 to 6.5. Contains sodium bisulfite as an additive.
  • Source is the Japanese package insert (Otsuka Pharmaceutical Factory, revised May 2026), translated; equivalence with the Vietnam-made Philippine product is not confirmed.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Usual adult dose 500 to 1000 ml by intravenous drip; standard rate 180 to 300 minutes per 500 ml (Japanese package insert).

Kidney notes

  • Contraindicated in severe renal impairment, except in patients on dialysis or hemofiltration: urea and other amino acid metabolites may accumulate and worsen symptoms (package insert, sections 2 and 9.2.1).
  • Even on dialysis or hemofiltration, urea and other metabolites may accumulate; removal depends on the dialysis method and the patient's condition. Check blood chemistry, acid-base balance and fluid balance before starting and while continuing (sections 8 and 9.2.2).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement). (AKI, acute kidney injury; CKD, chronic kidney disease; KF, kidney failure.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)

Bottom line

A hepatic amino acid infusion for encephalopathy in chronic liver disease. In severe renal impairment it is contraindicated unless the patient is on dialysis or hemofiltration, and even then urea and metabolites can accumulate: monitor blood urea, acid-base and fluid balance.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Aminosteril Infant

Aminosteril Infant 6% (Fresenius Kabi Austria GmbH) is a pediatric amino acid solution, registered in the Philippines as 100 ml glass bottles.

Composition

Per presentationAminosteril Infant 6%, per 1000 ml
L-isoleucine (g)4.8
L-leucine (g)7.8
L-lysine acetate (g)7.2
(= L-lysine, g)5.11
L-methionine (g)1.872
L-phenylalanine (g)2.25
L-threonine (g)2.64
L-tryptophan (g)1.206
L-valine (g)5.4
L-arginine (g)4.5
L-histidine (g)2.856
Glycine (g)2.49
L-alanine (g)5.58
L-proline (g)5.826
L-serine (g)4.602
Taurine (g)0.24
N-acetyl-L-tyrosine (g)3.106
(= L-tyrosine, g)2.52
N-acetyl-L-cysteine (g)0.42
(= L-cysteine, g)0.312
L-malic acid (g)1.572
Total amino acids (g)60
  • Lysine is given as L-lysine acetate, tyrosine as N-acetyl-L-tyrosine and cysteine as N-acetyl-L-cysteine; the equivalent free amino acid amounts are shown in the rows marked "=". The free amino acids add up to 60 g per liter (6%).
  • Without electrolytes and carbohydrates; contains taurine.
  • Same formulation as Aminoven Infant 10% (Fresenius Kabi), at 60% of its concentration.

Composition per 1000 ml of Aminosteril Infant 6% from the Philippine product information supplied by Dr. W. G. M. Rivero (November 18, 2026). Every value is exactly 0.6 times the Aminoven Infant 10% SmPC value, which confirms the same formulation at 6%.

Dose and rate limits

  • Continuous intravenous infusion through a central vein; maximum rate 0.1 g amino acids/kg/hour (Aminoven Infant SmPC 4.2). For the 6% solution, 1 g amino acids is 16.7 ml.
  • Maximum daily dose in g amino acids/kg: age 1 year 1.5 to 2.5 g/kg; 2 to 5 years 1.5 g/kg; 6 to 14 years 1.0 g/kg (Aminoven Infant SmPC 4.2; same in the South African PI). The Swiss text gives a preterm maximum of 2.5 g/kg/day. The SmPC's ml/kg figures are for the 10% solution and are not shown.

Kidney notes

  • Spanish SmPC and South African PI: patients with renal or hepatic insufficiency require an individualized dose; frequent monitoring includes urea nitrogen, ammonia, electrolytes, glucose and triglycerides (SmPC 4.4).
  • Swiss Fachinformation: renal insufficiency and unknown kidney function are listed as contraindications. National texts differ; follow the Philippine package insert.
  • Renal amino acid losses with amino acid imbalance can occur if the infusion is too rapid or in overdose (South African PI 4.8, 4.9).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).

Bottom line

A pediatric amino acid solution, 60 g amino acids per liter with taurine and no electrolytes or carbohydrates; the ESPEN 2021 kidney guideline quoted here covers hospitalized adults. Dose it in g amino acids/kg, not in ml from the 10% product's tables.

Not shown here

  • Osmolarity, total nitrogen and energy of the 6% solution: not in the supplied product information (the Aminoven Infant 10% values do not apply). Check the bottle label.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Aminosteril N-Hepa 8%

Aminosteril N-Hepa 8% (Fresenius Kabi Austria GmbH) is an amino acid solution enriched in branched-chain amino acids for parenteral nutrition in severe liver insufficiency, with or without hepatic encephalopathy. Philippine registration: 500 ml bottle. It is a hepatic formula, not a kidney formula.

Composition

Per presentationper 1000 ml
Amino acids (g)80
Nitrogen (g)12.9
Energy (kcal)320
L-leucine (g)13.09
L-isoleucine (g)10.4
L-valine (g)10.08
  • No electrolytes are listed apart from acetate as lysine monoacetate; theoretical osmolarity is not stated in the short SmPC.
  • Source is the Austrian manufacturer short SmPC (Fachkurzinformation) of Aminosteril Hepa 8% (March 2018), in German, translated; the Philippine product is registered as Aminosteril N-Hepa 8% (80 g/l). Confirm against the Philippine package insert.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Kidney notes

  • Renal insufficiency is listed as a contraindication, along with hypokalemia, metabolic acidosis, shock, hypoxia and general infusion contraindications (Fachkurzinformation, contraindications).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement). (AKI, acute kidney injury; CKD, chronic kidney disease; KF, kidney failure.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)

Bottom line

A hepatic (branched-chain-enriched) amino acid solution. The available SmPC lists renal insufficiency as a contraindication, so it is not a choice for a patient with kidney failure unless the current Philippine insert says otherwise; for hepatorenal patients, involve the nutrition team.

Not shown here

  • Maximum daily dose and infusion rate (not in the short SmPC).
  • Full special warnings (the short SmPC refers to the full Fachinformation).

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Aminoven

Aminoven 10% (Fresenius Kabi Austria GmbH) is a standard amino acid solution (100 g amino acids per liter) for parenteral nutrition. Philippine registrations: 500 ml and 1 L bottles. The SmPC lists no electrolytes.

Composition

Per presentationper 1000 ml
Amino acids (g)100
Nitrogen (g)16.2
Energy (kcal)400
  • Theoretical osmolarity 990 mosm/l; titratable acidity 22 mmol NaOH/l; pH 5.5 to 6.3. No sodium, potassium, chloride or phosphate is listed; lysine is present as the acetate salt (SmPC sections 2, 3, 6.1).
  • Source is the Irish SmPC of the 100 g/l product sold in Ireland as Aminoven 16 (its sections 5.3 and 6.3 refer to Aminoven 10%). Confirm against the Philippine package insert.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Maximum daily dose 20 ml/kg body weight (2.0 g amino acids/kg); maximum infusion rate 1.0 ml/kg/hour (0.1 g amino acids/kg/hour) (SmPC 4.2).

Kidney notes

  • Contraindicated in renal insufficiency without hemodialysis or hemofiltration treatment, and in fluid overload (SmPC 4.3).
  • Monitor serum electrolytes, fluid balance and renal function (SmPC 4.4). With hypokalemia or hyponatremia, potassium and/or sodium should be supplied at the same time (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A standard electrolyte-free amino acid solution: in renal insufficiency it is contraindicated unless the patient is on hemodialysis or hemofiltration. Dose protein to the ESPEN targets for the patient's setting and dialysis modality, and add electrolytes only as serum levels require.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Evamin

Evamin (Albert David Limited) is registered in the Philippines as an amino acid solution for injection in a 20 ml glass vial, and separately as an oral capsule of amino acids with multivitamins and minerals. Only the injection is a parenteral product.

Composition

Per presentationCapsule (oral, DRP-4561-03), per capsuleInjection (20 ml vial, DRP-3866-03), per ml
L-lysine (mg)2522.3
Glycine (mg)1010
L-histidine (mg)44
Vitamin B1 (mg)5not shown
Vitamin B2 (mg)3not shown
Vitamin B6 (mg)1.5not shown
Folic acid, vitamin B9 (mcg)500not shown
Vitamin B12 (mcg)2.5not shown
Vitamin C (mg)40not shown
Elemental iron (mg)49.5not shown
(as ferrous fumarate, mg)150not shown
Zinc sulfate (mg)50not shown
L-isoleucine (mg)not shown5.5
L-leucine (mg)not shown12.3
L-methionine (mg)not shown7.1
L-phenylalanine (mg)not shown8.7
L-threonine (mg)not shown5.4
L-tryptophan (mg)not shown1.8
L-valine (mg)not shown6.1
L-arginine (mg)not shown8
Sorbitol (mg)not shown50
  • Cells marked "not shown" are ingredients the other presentation does not list.
  • The oral capsule (DRP-4561-03) is not parenteral nutrition; it is listed only because it shares the brand name. Iron 49.5 mg is the elemental iron in 150 mg ferrous fumarate.
  • The injection carries sorbitol 50 mg/ml (5%) with essential amino acids plus arginine and glycine; it has no electrolytes listed.

Composition from the Philippine product information supplied by Dr. W. G. M. Rivero (November 18, 2026): per capsule for the oral capsule (DRP-4561-03) and per ml for the 20 ml injection (DRP-3866-03).

Kidney notes

  • SmPC kidney text withheld pending the package insert.
  • The capsule supplies iron and zinc: account for it in iron studies and when another oral iron or zinc is prescribed.

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).

Bottom line

Two different products share the name: an oral capsule of three amino acids with B vitamins, vitamin C, iron and zinc, and a 20 ml amino acid injection with 5% sorbitol. Neither is a complete nutrition source; count the injection's small amino acid load in the protein plan.

Not shown here

  • Dosing and SmPC kidney text for both registrations: not in the supplied product information.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Nephrosteril

Nephrosteril (Fresenius Kabi) is a 7% amino acid solution for infusion without carbohydrates or electrolytes, intended for patients with renal insufficiency: 60% essential, 13% conditionally essential and 27% non-essential amino acids. Philippine registration: 250 ml and 500 ml glass bottles.

Composition

Per presentationper 1000 ml
L-isoleucine (g)5.1
L-leucine (g)10.3
L-lysine monoacetate (g)10.01
(= L-lysine, g)7.1
L-methionine (g)2.8
Acetylcysteine (g)0.5
(= L-cysteine, g)0.37
L-phenylalanine (g)3.8
L-threonine (g)4.8
L-tryptophan (g)1.9
L-valine (g)6.2
L-arginine (g)4.9
L-histidine (g)4.3
Aminoacetic acid (glycine) (g)3.2
L-alanine (g)6.3
L-proline (g)4.3
L-serine (g)4.5
L-malic acid (g)1.5
Glacial acetic acid (g)1.38
Total amino acids (g)70
Total nitrogen (g)10.8
Energy (kJ)1210
Energy (kcal)280
  • The manufacturer describes it as a 7% amino acid solution without carbohydrates and electrolytes (Fresenius Kabi India product page).
  • Theoretical osmolarity 645 to 770 mosm/l; manufacturer texts quote different values within this range, so check the bottle label. Energy 1210 kJ (280 kcal) per liter.
  • Lysine is given as L-lysine monoacetate and cysteine as acetylcysteine; the equivalent free amino acid amounts are shown in the rows marked "=".

Composition from the Fresenius Kabi India product page (accessed November 17, 2026), matching the product information supplied by Dr. W. G. M. Rivero. Theoretical osmolarity 645 to 770 mosm/l per Dr. Rivero (November 18, 2026).

Dose and rate limits

  • Acute and chronic renal insufficiency without dialysis: up to 0.5 g amino acids/kg body weight per day (500 ml per day at 70 kg).
  • Acute and chronic renal insufficiency on hemodialysis, hemofiltration or peritoneal dialysis: up to 1 g amino acids/kg body weight per day (1000 ml per day at 70 kg) (Fresenius Kabi India product page).

Kidney notes

  • Uses stated by the manufacturer: total or partial parenteral nutrition in acute or chronic renal insufficiency, with or without kidney replacement therapy, and intradialytic amino acid supplementation in maintenance hemodialysis.
  • It supplies amino acids only (no glucose, lipid or electrolytes): energy, electrolytes, vitamins and trace elements must be given separately and monitored.

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A renal amino acid formula (70 g amino acids per liter, no carbohydrates or electrolytes). ESPEN 2021 does not support routine use of kidney-specific PN formulas over conventional ones (Recommendation 24); concentrated renal formulas may be preferred in selected patients with electrolyte and fluid imbalances (Recommendation 26). Count it in the protein prescription and add energy and electrolytes separately.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Dosage forms

Philippines

  • Solution for iv infusion: 50 mg/mL, 80 g/L, 100 mL contains: L-Glutamic Acid-900 mg L-Proline-810 mg L-Serine-750 mg L-Phenylalanine-550 mg L-Leucine-530 mg L-Lysine HCI-490 mg L-Valine-430 mg L-Aspartic Acid-410 mg L-Isoleucine-390 mg L-Arginine HCI-330 mg L-Alanine-300 mg L-Threonine-300 mg L-Histidine HCI-240 mg L-Glycine-210 mg L-Methionine-190 mg L-Tryptophan-100 mg L-Tyrosine-50 mg L-Cysteine HCI-14.50 mg, 100 mL contains: L-Glycine-760.00 mg L-Threonine-250.00 mg L-Phenylalanine -534.00 mg L-Methionine-225.00 mg L-Arginine HCI-500.00 mg L-Alanine-200,00 mg L-Leucine-490.00 mg L-Proline-100.00 mg L-Lysine HCI-430.00 mg L-Serine-100.00 mg L-Valine-360.00 mg L-Tryptophan-90.00 mg L-Isoleucine-352.00 mg L-Glutamic Acid-75.00 mg L-Aspartic Acid -250.00 mg L-Tyrosine-25.00 mg L-Histidine HCI-250.00 mg L-Cystine HCI-10.00 mg
  • Solution for injection
  • Solution for infusion
  • Solution for injection for i.v: 7.00 mg 6.00 mg L-Serine L-Valine 3.25 mg 3.10 mg L-Proline 5.60 mg L-Phenylalanine 2.55 mg Glycine 5.50 mg L-Isoluecine 2.50 mg L-Leucine L-Lysine HCI (eq. to L-Lysine) 3.70 mg 3.30 mg L-threonine 2.20 mg L-Methionine L-Histidine HCI H2 O (eq. to L-Histidine) L-Tryptophan Taurine L-Tyrosine 2.15 mg 1.50 mg 1.00 mg 500 mcg 200 mcg

Registered products in the Philippines

24 products registered with the Food and Drug Administration (FDA) Philippines list Amino acids as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Amino Acids Crystalline (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products24
Philippine FDA-registered products for Amino acids
Package insert
AlaminAmino Acids
(see reverse for formulation) Solution for InjectionClear Glass Vial x 20 mL with Blue Flip-off seal (Box of 1's)
Rx
Albert David LimitedIndia
Ellebasy Medicale TradingImporter: Medethix, Inc.
DRP-3866-01
Jul 30, 2031
AminofastAmino Acids
(See reverse for formulation) Solution for Injection (IV)Type I Glass Ampoule x 20 mL (Box of 5's)
Rx
Taiwan Biotech Co., Ltd.R.O.C
Medirich Pharma Distribution Corp.Importer: Largen Med., Inc.
DRP-3875-01
Jan 18, 2029
Aminogen-SAmino Acids
3% Solution for Injection (I.V)USP Type II Glass Vial x 500 mL
Rx
TAIWAN BIOTECH CO., LTD.R.O.C
LARGEN MED INC.
DRP-1301
Nov 17, 2028
AminolebanAmino Acids
8% w/v Solution for I.V. InfusionLDPE Bottle with Rubber Stopper x 500 mL
Rx
Otsuka Pharmaceutical Vietnam Joint Stock CompanyVietnam
Zuellig Pharma CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc.
DR-XY37373
Jan 19, 2030
AminolebanAmino Acids
8% w/v Solution For I.V. InfusionPolypropylene Softbag x 200 mL and 500 mL
Rx
Otsuka Pharmaceutical Vietnam Joint Stock CompanyVietnam
Otsuka (Philippines) Pharmaceutical, Inc.
DR-XY49750
Jun 11, 2031
AminomynAmino Acids
3% Solution for Injection (IV)USP Type II Glass Vial x 500 mL
Rx
Taiwan Biotech Co., LtdR.O.C
VGV MEDISPEC INCORPORATEDImporter: Largen Med Inc.
DRP-1301-02
Nov 17, 2028
Aminoplasmal B. Braun 5% EAmino Acids CrystallineVariant spelling
Solution for Infusion
Rx
B. Braun Melsungen AG
—
DR-XY40354
Dec 15, 2026
Aminosil5.4% Amino Acids
Solution for IV InfusionUSP Type II Colorless and Transparent Glass Bottle in 250mL and 500mL (Box of 10's)
Rx
Dai Han Pharm. Co., Ltd.Republic of Korea
JLT Pharma Inc.
DRP-9333
Nov 20, 2029
Aminosteril InfantAmino Acids
6 % Solution for I.V. InfusionType I Glass Bottle x 100 mL
Rx
Fresenius Kabi Austria GmbHAustria
Fresenius Kabi Philippines, Inc.
DR-XY23408
Oct 20, 2027
Aminosteril N-Hepa 8%Amino Acids
80 g/L (8% w/v) (see reverse for formulation) Solution for IV InfusionType II Clear Glass Botlle with Halobutyl Rubber Stopper and Aluminum Cap x 500 mL
Rx
Fresenius Kabi Austria GmbHAustria
Fresenius Kabi Philippines, Inc.
DR-XY43958
Dec 4, 2029
AminovenAmino Acids
10% Solution for IV InfusionType II colorless glass bottle closed with halobutyl rubber stopper and aluminium flip-off cap x 500 mL and 1 L
Rx
Fresenius Kabi Austria GmbHAustria
Importer: Fresenius Kabi Philippines, Inc.
DR-XY48149
Jun 30, 2027
Aminovit5.4% Amino Acids
(see reverse for formulation) Solution for IV InfusionUSP Type II Colorless and Transparent Glass Bottle in 500 mL (Box of 10's)
Rx
Dai Han Pharma. Co., Ltd.Republic of Korea
Largen Med Inc.Importer: JLT Pharma, Inc.
DRP-9333-01
Nov 20, 2029
AminovitAmino Acids
50 mg/mL (5% w/v) Solution for Injection for I.V. Infusion [see reverse for formulation]USP Type II transparent glass bottle with chlorobutyl rubber stopper and sealed with aluminum cap and LDPE plastic hanging ring x 500 mL (net content) (Box of 1's)
Rx
Siu Guan Chem. Ind. Co., Ltd.Taiwan (R.O.C.)
Mark Ericson Enterprises, Inc.Importer: Largen Med Inc.
DRP-11275-01
Feb 22, 2027
Chiamin-AAmino Acids
Each mL contains: L-Alanine L-Arginine HCI (eq. to L-Argine) 7.00 mg 6.00 mg L-Serine L-Valine 3.25 mg 3.10 mg L-Proline 5.60 mg L-Phenylalanine 2.55 mg Glycine 5.50 mg L-Isoluecine 2.50 mg L-Leucine L-Lysine HCI (eq. to L-Lysine) 3.70 mg 3.30 mg L-threonine 2.20 mg L-Methionine L-Histidine HCI H2O (eq. to L-Histidine) L-Tryptophan Taurine L-Tyrosine 2.15 mg 1.50 mg 1.00 mg 500 mcg 200 mcg Solution for Injection for I.V.USP Type II transparent glass bottle with chlorobutyl rubber stopper and sealed with aluminum cap and LDPE plastic hanging ring x 500 mL (net content) (Box of 1's)
Rx
Siu Guan Chem. Ind. Co., Ltd.Taiwan
Caan Pharmaceutical Co., Inc.
DRP-11275
Feb 22, 2027
DecaminAmino Acids
10% w/v Solution for Injection(Intravenous Infusion) [see formulation on reverse side]USP Type II Clear Glass Bottle x 250 mL and 500 mL
Rx
Dai Han Pharm. Co., Ltd.Republic of Korea
JLT Pharma, Inc.
DRP-9335
Feb 17, 2028
EvaminAmino Acids
(see reverse for formulation) Solution for InjectionClear Glass Vial with Blue Flip-off Seal x 20 mL (Box of 1 's)
Rx
Albert David LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-3866-03
Jun 23, 2031
Minosol-5%Amino Acids
50mg/mL (5% w/v) Solution for IV InfusionUSP Type II Clear Glass Bottle x 250mL (net content) Not Applicable
Rx
Jiangsu Pengyao Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY44968
Dec 21, 2030
NephrosterilAmino Acids
7% Solution for Intravenous Infusion (see reverese)Type II Hydrolytic Resistance Glass Bottle x 250 mL and 500 mL
Rx
Fresenius Kabi Austria GmbHAustria
Fresenius Kabi Philippines IncImporter: Fresenius Kabi Philippines, Inc.
DR-XY18649
Feb 17, 2030
NutrilonAmino Acids
Solution for InjectionClear Glass Vial with Blue Flip-off Seal x 20 mL (Box of 1's)
Rx
Albert David LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.
DRP-3866-02
Jun 9, 2031
Nutrimax7% Amino Acids
Formulation: Each 100 mL contains: L-Glutamic Acid-900mg L-Proline-810mg L-Serine-750mg L-Phenylalanine-550mg L-Leucine-530mg L-Lysine HCI-490mg L-Valine-430mg L-Aspartic Acid-410mg L-Isoleucine-390mg L-Arginine HCI-330mg L-Alanine-300mg L-Threonine-300mg L-Histidine HCI-240mg L-Glycine-210mg L-Methionine-190mg L-Tryptophan-100mg L-Tyrosine-50mg L-Cysteine HCI-14.50mg Solution For IV InfusionType III Glass Bottle x 250 mL and 500 mL (Net Content)
Rx
Cisen Pharmaceutical Co., Ltd.China
Endure Medical, Inc.Trader: Xiamen Runcheng Pharma Group Co., Ltd.
DR-XY46757
Oct 28, 2027
Nutrimax5% Amino Acids
Formulation: Each 100 mL contains: L-Glycine-760.00 mg L-Threonine-250.00 mg L-Phenylalanine -534.00 mg L-Methionine-225.00 mg L-Arginine HCI-500.00 mg L-Alanine-200,00 mg L-Leucine-490.00 mg L-Proline-100.00 mg L-Lysine HCI-430.00 mg L-Serine-100.00 mg L-Valine-360.00 mg L-Tryptophan-90.00 mg L-Isoleucine-352.00 mg L-Glutamic Acid-75.00 mg L-Aspartic Acid -250.00 mg L-Tyrosine-25.00 mg L-Histidine HCI-250.00 mg L-Cystine HCI-10.00 mg Solution For IV InfusionType III Glass Bottle x 250 mL and 500 mL (Net Content)
Rx
Cisen Pharmaceutical Co., Ltd.China
Endure Medical, Inc.Trader: Xiamen Runcheng Pharma Group Co., Ltd.
DR-XY46758
Oct 13, 2027
NutriminAmino Acids
(see reverse for formulation) Solution for InjectionClear Glass Vial with Blue Flip-off Seal x 20 mL (Box of 1 's)
Rx
Albert David LimitedIndia
Medethix, Inc.
DRP-3866
Jul 26, 2031
PharmineAmino Acids
3% Solution For Injection (IV)USP Type II Glass Vial with rubber stopper and blue flip-off seal x 500 mL
Rx
TAIWAN BIOTECH CO., LTD.China
PHARMA KING DISTRIBUTORImporter: LARGEN MED INC.
DRP-1301-01
Nov 17, 2028
Zuricure5.4% Amino Acids
Solution for IV InfusionUSP Type II Colorless and Transparent Glass Bottle in 250mL and 500mL (Box of 10's)
Rx
Dai Han Pharm. Co., Ltd.Republic of Korea
Speed Cure Pharma, OpcImporter: JLT Pharma Inc.
DRP-9333-02
Nov 20, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Amino Acids, Crystalline Standard 8%, 500 mL Plastic Bottle₱485.65–₱920.00Reference ₱506.00per bottleDPRI procurement range
Amino Acids, Crystalline Standard 9.12%, 20 mL Ampule₱119.10–₱145.80Reference ₱119.10per ampuleDPRI procurement range
Amino Acids, Crystalline Standard 10%, 500 mL Plastic Bottle₱730.00–₱800.00Reference ₱730.00per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Amino Acids, Crystalline Standard
PNF listingInj.: 3.5%, 500 mL bottle (IV infusion)
PNF listingInj.: 5%, 100 mL, 250 mL and 500 mL bottle (IV infusion)
PNF listingInj.: 6%, 100 mL and 250 mL bottle (IV infusion)
PNF listingInj.: 7%, 8.5%, 10%, and 11.4%, 100 mL, 500 mL and
PNF listingInj.: 1 L bottle (IV infusion)
PNF listingInj.: 8%, 500 mL bottle (IV infusion) (as branched chain)
PNF listingInj.: 9.12%, 20 mL ampul and 200 mL bottle (IV infusion)
PNF listingInj.: 10%, 100 mL and 500 mL bottle (IV infusion)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  3. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  4. Otsuka Pharmaceutical Factory, Inc. (2026). Aminoleban intravenous infusion [Package insert, 2nd edition, revised May 2026; Japanese]. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/180079_3253404A3055_1_09
  5. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
  6. Fresenius Kabi España. (n.d.). Aminoven Infant 10% solución para perfusión [Ficha técnica]. Agencia Española de Medicamentos y Productos Sanitarios, CIMA. Retrieved November 17, 2026, from https://cima.aemps.es/cima/dochtml/ft/59628/FT_59628.html https://cima.aemps.es/cima/dochtml/ft/59628/FT_59628.html
  7. Fresenius Kabi South Africa. (2022). Aminoven Infant 10% [Professional information, approved October 19, 2022]. South African Health Products Regulatory Authority. https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2022/11/Aminoven-Infant-10-Approved-PI-19.10.2022.pdf https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2022/11/Aminoven-Infant-10-Approved-PI-19.10.2022.pdf
  8. Fresenius Kabi. (n.d.). Aminoven Infant 10% Infusionslösung [Fachinformation]. Compendium.ch. Retrieved November 17, 2026, from https://compendium.ch/de/product/index/1551438-aminoven-infant-sol-perf-10-1000ml https://compendium.ch/de/product/index/1551438-aminoven-infant-sol-perf-10-1000ml
  9. Fresenius Kabi. (n.d.). Aminoven Infant 10% [Product information]. Retrieved November 17, 2026, from https://www.fresenius-kabi.com/mena/products/medical-nutrition/parenteral-nutrition-/amino-acids/aminoven--infant-10- https://www.fresenius-kabi.com/mena/products/medical-nutrition/parenteral-nutrition-/amino-acids/aminoven--infant-10-
  10. Fresenius Kabi Austria GmbH. (2018). Aminosteril Hepa 8 % Infusionslösung [Fachkurzinformation (short summary of product characteristics), March 2018; German]. https://fresenius-kabi.com/content/dam/fresenius-kabi/at/documents/fki/Aminosteril_Hepa_FKI_Mrz_2018.pdf.coredownload.inline.pdf
  11. Fresenius Kabi. (2019). Aminoven 16, solution for infusion (PA2059/025/002) [Summary of product characteristics; text revised April 2019]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/18332/Licence_PA2059-025-002_05042019163245.pdf
  12. Fresenius Kabi India. (n.d.). Nephrosteril [Product information]. Retrieved November 17, 2026, from https://www.fresenius-kabi.com/in/products/nephrology/nephrosteril https://www.fresenius-kabi.com/in/products/nephrology/nephrosteril

renalcarematters.com content: Parenteral nutrition kidney notes (Aminoleban): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Aminosteril Infant): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026. Parenteral nutrition kidney notes (Aminosteril N-Hepa 8%): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Aminoven): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Evamin): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026. Parenteral nutrition kidney notes (Nephrosteril): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .